A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells

Area of Science:

• Immunology
• Ophthalmology
• Biotechnology

Background:

• Autoimmune uveitis is a sight-threatening condition with limited treatment options.
• Corticosteroids are standard but have adverse effects.
• Interleukin-6 (IL-6) plays a key role in autoimmune uveitis, promoting Type 17 helper T cell differentiation.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a novel anti-IL-6Rα nanobody in experimental autoimmune uveitis (EAU).
• To assess the nanobody's effect on T cell differentiation and inflammatory mediators.
• To investigate the translational relevance using patient-derived cells.

Main Methods:

• Treatment of EAU mouse models with anti-IL-6Rα nanobody.
• Analysis of T cell populations (Th17, Th1) and inflammatory cytokines.
• In vitro studies using peripheral blood mononuclear cells (PBMCs) from Vogt-Koyanagi-Harada (VKH) patients.

Main Results:

• The anti-IL-6Rα nanobody suppressed both Th17 and Th1 cells.
• Significant reduction in inflammatory mediators and amelioration of disease severity in EAU models.
• Effective suppression of interferon-γ (IFN-γ) and IL-17 production in VKH patient PBMCs.

Conclusions:

• Anti-IL-6Rα nanobody demonstrates significant therapeutic potential for autoimmune uveitis.
• The nanobody targets key inflammatory pathways involved in the disease.
• This approach offers a promising alternative to current treatments for non-infectious uveitis.